ArticleJCEM case reports2025
A Unique Case of Metastatic Paraganglioma in a Patient With Parkinson Disease.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the case of a patient in his 70s with Parkinson disease (PD) who had an incidental pheochromocytoma with mesenteric secondaries. Although the literature contains a few case reports of patients with PD who have incidental pheochromocytoma, this is the first case report of a patient with PD and metastatic paraganglioma (PPGL). The diagnosis was confirmed by a metaiodobenzylguanidine radioisotopic scan, along with increased levels of catecholaminergic products and byproducts in the urine. Genetic predisposition to PD and PPGL appears paradoxical, as PPGL is associated with the pathologic stabilization of hypoxia-inducible factor-1α. In contrast, PD involves the disruption of hypoxia-inducible factor-1α activity. Thus, the coexistence of these 2 conditions should be very rare, and, based on the paucity of such cases in the literature, this appears to be the case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.